In a clinical trial called CHECKMATE-040, patients with hepatocellular carcinoma who progressed on or were intolerant to sorafenib were given Opdivo or Opdivo and Yervoy followed by Opdivo. The complete response rate was 8% in patients taking Opdivo and Yervoy, and the partial response rate was ...
Opdivo + Yervoy: 23.7 months (95% CI: 18.8-29.4) vs. 20.6 months with lenvatinib or sorafenib (95% CI: 17.5-22.5). CheckMate-040 Overall response rate Opdivo + Yervoy every 3 weeks (4 doses) then Opdivo every 2 weeks (Arm A): 32% (95% CI 20-47) ...
et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Rev. Drug Discov 5, 835–844 (2006). Article CAS Google Scholar Goke, R. et al. Exendin-4 is a high potency agonist and truncated exendin-(9–39)-amide an antagonist at the glucagon-like...
Geier A, Macias RI, Bettinger D, Weiss J, Bantel H, Jahn D, Al-Abdulla R, Marin JJ (2017) The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma. Oncotarget 8:15846–15857 ...
To fast or not to fast? How food could impact on the absorption of kinase inhibitors and its economical valueCancer ResearchOncologyPresently, cancer patients receiving oral kinase inhibitors are suggested to take the drug with an empty stomach or, in the case of drugs such as Sorafenib which ...
Sorafenib can promote the interaction of ferroptosis suppressor protein 1 (FSP1) and TRIM54 to accelerate FSP1 degradation by inducing the ubiquitination of FSP1 [42]. FSP1 performs redox functions primarily at the plasma membrane, reduces CoQ10, and acts as a lipophilic radical-trapping ...
Ippolito, D., Querques, G., Okolicsanyi, S., Franzesi, C. T., Strazzabosco, M. & Sironi, S. Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: a feasibility...
Preclinical studies suggest that the FLT3 inhibitor sorafenib induces interleukin 15 production from FLT3-ITD cells in the postallograft setting, enhancing effector T-cell graft-versus-leukemia activity.36 In support of this concept, a phase 2 randomized study in FLT3-ITD AML showed improved relapse...
Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patient... Background The incidence of thyroid cancer and the number of patients who die from this disease are increasing globally. Differentiated thyroi...
Furthermore, multikinase inhibitors (MKIs), including sorafenib and lenvatinib, are increasingly being used as alternative medical treatments in the most advanced forms, especially in differentiated thyroid cancer refractory to RAI. In the literature, advanced DTC (ADTC) is defined by the presence of...